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RESUMO
A disseção isolada da aorta abdominal é um evento raro. A sua história natural e tratamento ideal não estão totalmente esclarecidos. 
A intervenção endovascular tem ganho uma preponderância crescente. A disseção crónica isolada da aorta abdominal está ainda 
menos descrita na literatura. Descrevemos três casos de doentes com disseção crónica isolada da aorta abdominal submetidos a 
tratamento endovascular na nossa instituição. A média de idades dos doentes era de 82 anos. A indicação terapêutica foi degeneração 
aneurismática. O diâmetro aórtico médio à apresentação era de 46,7 mm. Não houve mortalidade ou reintervenção peri-operatória. O 
seguimento pós-operatório médio foi de 5,3 anos (2-12 anos). Realizou-se reintervenção tardia num doente, oito anos após a cirurgia 
inicial, por endofuga tipo I. Segundo a nossa curta experiência o tratamento endovascular representa uma opção terapêutica eficaz na 
disseção crónica isolada da aorta abdominal. O follow-up alargado é mandatório. São necessários estudos com maiores amostras e 
follow-up para melhor compreender esta patologia.
Palavras-chave: Aneurisma da Aorta Abdominal; Aneurisma Dissecante; Implante de Prótese Vascular; Procedimentos Endovascu-
lares.
ABSTRACT
Isolated acute abdominal aortic dissection is a relatively rare event. Its natural history is not fully understood and its optimal treatment is 
not established. Open surgery represents the most described treatment but endovascular intervention has had increasing application. 
Isolated chronic abdominal aortic dissection  is even less described in the literature. We describe three patients with isolated chronic 
abdominal aortic dissection who underwent endovascular treatment in our institution. Mean age at presentation was 82 years. 
Indication for surgical intervention was aneurismal degeneration. Mean aortic diameter at presentation was 46.7 mm. There was no 
perioperative mortality or reinterventions. Mean follow-up was 5.3 years (2-12 years). Late reintervention was needed in one patient, 
eight years after initial surgery, due to type 1 endoleak. According to our experience, endovascular intervention represents an effective 
and durable treatment option in isolated chronic abdominal aortic dissection. However, long-term follow-up is mandatory. Furthermore, 
larger studies are still needed to understand this disease and its adequate treatment.  
Keywords: Aneurysm, Dissecting; Aortic Aneurysm, Abdominal; Blood Vessel Prosthesis Implantation; Endovascular Procedures.
INTRODUCTION
 The thoracic aorta is the most commonly involved 
aortic section when acute aortic dissection (AD) occurs. It 
may also extend to the abdominal aorta.1 However, acute 
isolated abdominal aortic dissection (IAAD) is a relatively 
rare event, representing only 1% to 4% of the AD cases, 
with only 18 cases reported in the International Registry of 
Acute Aortic Dissection (IRAD) between 1996 and 2003.2,3 
It can occur spontaneously or in association with trauma 
and surgical procedures (specially endovascular).4-6 The 
association with atherosclerosis or an iatrogenic etiology is 
stronger for acute IAAD than for classical Stanford type B 
AD. Acute IAAD most commonly presents with abdominal 
pain, visceral ischemia (including acute renal failure) and 
limb ischemia. Mean reported age of presentation is 67.7 
± 13.3 years2, similar to that of classical type B aortic 
dissection. 
 Medically treated chronic dissection tends to progress 
with aneurysmal degeneration. Due to wall weakening 
induced by chronic dissection, with higher rupture risk, 
many surgeons advise earlier intervention in dissecting 
aneurysms, usually when they reach a diameter of 3 cm.1,6,7 
 In result of the scarcity of reported cases, management 
of IAAD is still a matter of controversy. We describe three 
cases of chronic IAAD who underwent endovascular 
treatment. These cases occurred during a time frame of 10 
years and no other cases of IAAD were described in our 
institution during this period.
CASE REPORT
Case 1
 An asymptomatic abdominal aortic aneurysm was 
found on duplex ultrasound in a 78 year-old male with 
hypertension. CT angiography (CTA) revealed an 85mm 
fusiform infra-renal AAA with an associated isolated 
abdominal aortic dissection (CTA images not available). 
The thoracic aorta had a normal diameter and lumen. 
 The patient was considered fit for open surgery but due 
to his preference endovascular treatment was chosen. A 
bifurcated abdominal aortic Talent endograft (Medtronic 
Vascular, USA) was deployed through a bilateral femoral 
cutdown. No early, medical or surgical, postoperative 
complications were observed. 
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Figure 1 - Chronic IAAD in the distal infra-renal aorta extending to 
the mid third of the right external iliac artery (EIA) with a right iliac 
artery aneurysm in an 83 year old male
 
Figure 2 -  A 25 mm saccular aneurysm proximal to the aortic 
bifurcation in relation to a chronic IAAD in an 85 year old female
 During follow-up a consistent reduction of aortic 
diameter was observed with a maximum aortic diameter 
at year 7 of 73 mm with no endoleaks. During the 8th year 
post-EVAR the patient repeated a CTA which revealed an 
endoleak (suggestive of type III EL) and growth of aneurysm 
diameter (79,7 mm). EVAR was chosen to treat this late 
complication, intra-operative angiography revealed a type 
Ia endoleak which was treated with an aorto-uni-iliac stent 
graft (to ensure that a possible associated type III EL would 
be treated as well) and cross-over femoro-femoral bypass. 
Two early surgical reinterventions were performed to drain 
groin hematomas. At the 12th year of follow-up (four years 
after reintervention), the patient was asymptomatic and CTA 
showed aneurysm diameter stabilization at 80 mm with no 
endoleaks.
Case 2
 An 83 year-old male presented with an asymptomatic 
iliac dissecting aneurysm discovered on a CT during the 
follow-up of a urinary bladder adenocarcinoma. Patient was 
an ex-smoker, with stage 3 CKD (glomerular filtration rate 
of 30-59 mL/min). CTA showed an IAAD beginning distal to 
the inferior mesenteric artery’s (IMA) origin and extending 
to the mid third of the right external iliac artery (EIA) with a 
right iliac artery aneurysm with a maximum diameter of 30 
mm and a proximal neck length (to the aortic bifurcation) of 
22 mm (Fig. 1). Distal aortic diameter was 25 mm and both 
the left CIA and external iliac arteries measured 15 mm in 
diameter. 
 Endovascular treatment was chosen. Through a bilateral 
open femoral access, an Excluder endograft (W.L. Gore & 
Associates, Flagstaff, Arizona, USA) was implanted and 
extended to the EIA on the right side. No early, medical or 
surgical, postoperative complications were observed. 
 During follow-up (33 months), the patient presented 
a tolerated right gluteal claudication. Follow-up CTA’s 
revealed a reduction of iliac aneurysm’s diameter to 25 mm 
with no endoleaks.
Case 3
 An 85 year-old female, without known cardiovascular 
risk factors, was diagnosed with a saccular aneurysm of 
the terminal abdominal aorta on DUS. CTA confirmed a 25 
mm saccular aneurysm proximal to the aortic bifurcation in 
relation to an IAAD originating at the IMA level and with a 
reentry point 15mm proximal to the aortic bifurcation (Fig. 
2). She had a proximal, infra-renal, neck measuring 40mm 
in length without angulation. The maximum aortic diameter 
was 16 mm with 15 mm at the bifurcation level; right and left 
CIA’s measured 9 mm and 8 mm respectively.
 Due to patient’s age and suitable anatomy it was decided 
to proceed with endovascular treatment. Surgical femoral 
access was obtained to deliver an Endurant II endograft 
(Medtronic Vascular, USA) iliac limb 20 x 80 mm trimmed 
down to 70 mm length (Fig. 3). No early, medical or surgical, 
postoperative complications were observed. 
 At 24 months of follow-up the patient was asymptomatic 
and aneurysm sac shrinkage (20 mm of maximum diameter) 
without endoleaks was confirmed on CTA.
DISCUSSION
 Treatment strategies for acute IAAD include open 
surgery, endovascular intervention or medical treatment. 
The results from a meta-analysis published by Jonker et 
al8 suggest that an early aggressive (open or endovascular 
surgery) may be associated with improved survival. 
However this is a retrospective study with only 19 patients 
treated with endografts, therefore, in our institution, we still 
manage the AIAAD with medical treatment and treat these 
patients in case of ischemic complications. In the chronic 
phase we perform surgery if they develop an aneurysm (> 3 
cm or saccular morphology).
 Despite the good historical results described for open 
surgery,1,2,6 especially in good risk patients, the evolution of 
endovascular therapies has allowed the effective treatment 
of high operative risk patients with good long-term results9. 
In fact, the excellent results obtained by some centers 
supports endovascular techniques as the first-line treatment 
in all patients given the presence of adequate anatomy.9,10 
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Figure 3 -  Saccular dissecting aortic aneurysm treated with an 
Endurant II (Medtronic Vascular, USA) iliac limb 20 x 80 mm 
trimmed down to 70 mm length
 We emphasize the fact that all 3 cases described above 
were old patients at presentation (the younger patient was 
78 years-old), older than the mean age reported in most 
studies both for chronic IAAD and classical type B aortic 
dissection. This fact was also accounted for the choice 
of an endovascular approach. However, in our institution, 
age itself isn’t a criterion for treatment’s selection; in fact, 
comorbidities, anatomic criteria and the patient’s informed 
decision play a preponderant role. Despite old age, no early 
deaths were observed and the sole reintervention occurred 
eight years after the initial procedure due to a late endoleak. 
This reflects that endovascular treatment is effective in 
appropriately selected patients but also underlines the 
importance of maintaining long-term clinical and imaging 
follow-up. In our institution patients treated for chronic IAAD 
enter the same follow-up protocol as those treated with 
endografts for AAA (CTA at 3, 9 months after surgery and 
then yearly).
 In chronic IAAD, due to aortic wall weakening, adequate 
neck (defined as the normal infra-renal aorta above the 
proximal intimal tear/aneurysm sac) are imperative to allow 
good seal and prevent graft migration (> 15 mm in length, 
diameter < 28 mm and angulation < 60). 
 Case 3 also shows that even in cases with inadequate 
anatomy for conventional abdominal aortic endografts, 
presenting with small aortic and iliac diameters, modified 
endovascular techniques have the flexibility to provide safe 
and effective treatment given an adequate sealing zone.
 The retrospective nature of this case-series is one of the 
limitations of this report. The small sample also precludes 
any definitive conclusions. The long time lapse between the 
treated cases can also introduce a bias in the results due 
to the evolution of better endovascular devices and of the 
surgeons’ endovascular skills.
CONCLUSION
 Our results show that endovascular treatment for chronic 
IAAD is feasible, effective and durable. However, long-term 
follow-up is mandatory as late endoleaks may occur. Due 
to its rarity, chronic IAAD is still a relatively understudied 
pathology and its optimal treatment is not well established. 
Therefore, we consider that further multicentre studies with 
long-term follow-ups are necessary; however, these are 
unlikely to be expected due to the rarity of the pathology. 
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RESUMO
A elastose perfurante serpiginosa é uma dermatose perfurante rara, encontrada sobretudo em adolescentes e adultos jovens, cara-
terizada pela eliminação transepidérmica de fibras elásticas anómalas. O único fármaco conhecido capaz de induzir elastose perfu-
rante serpiginosa é a D-penicilamina. Descrevemos o caso de uma doente de 52 anos com pápulas queratósicas confluentes com 
disposição anular e crescimento centrífugo, localizadas na região cervical anterior. A doente estava cronicamente medicada com 
D-penicilamina, por doença de Wilson. A biópsia lesional revelou eliminação transepidérmica de fibras elásticas com aumento da 
eosinofilia, espessadas, ramificadas e de aspeto em dentes de serra. Os achados clinicopatológicos foram compatíveis com elastose 
perfurante serpiginosa secundária à D-penicilamina. Estima-se que a elastose perfurante serpiginosa ocorra em 1% dos doentes med-
icados com D-penicilamina. Bloqueando direta ou indiretamente as ligações cruzadas de desmosina da elastina, a D-penicilamina leva 
à síntese de fibras elásticas anómalas dérmicas, mas também extracutâneas. A elastose perfurante serpiginosa pode ser a primeira 
manifestação de um processo degenerativo multissistémico do tecido conjuntivo elástico.
Palavras-chave: Degeneração Hepatolenticular; Doenças da Pele/induzida quimicamente; Penicilamina; Quelantes/uso terapêutico.
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ABSTRACT
Elastosis perfurans serpiginosa (EPS) is a rare perforating dermatosis found primarily in adolescents and young adults, characterized 
by transepidermal elimination of abnormal elastic fibers. The only drug known capable of inducing EPS is D-penicillamine.  We report 
the case of a 52 year-old woman with keratotic papules arranged in an annular pattern with central clearing and centrifugal growth, 
located in the anterior cervical region. The patient was chronically treated with D-penicillamine for Wilson disease. Lesion biopsy 
showed transepidermal elimination of thickened, eosinophilic, branched, sawtooth-like elastic fibers. The clinical and pathological 
findings were consistent with EPS secondary to D-penicillamine. It is estimated that EPS occurs in 1% of patients treated with 
D-penicillamine. By blocking directly or indirectly the desmosine cross-links between elastin molecules, D-penicillamine leads to the 
synthesis of abnormal dermal and extracutaneous elastic fibers. EPS may be the first manifestation of a multisystemic degenerative 
process of elastic connective tissue.
Keywords: Chelating Agents/therapeutic use; Hepatolenticular Degeneration; Penicillamine; Skin Diseases/chemically induced.
INTRODUÇÂO
 A elastose perfurante serpiginosa (EPS) é uma entidade 
rara que pertence ao grupo das “dermatoses perfurantes 
primárias” onde se incluem a colagenose perfurante reati-
va, as foliculites perfurantes e a doença de Kyrle.1
 O conceito “dermatose perfurante adquirida” é usado 
por alguns autores, em sentido lato, para incluir as formas 
primárias que surgem no contexto de diabetes mellitus, 
doença renal crónica, ou ambas.2
 As dermatoses perfurantes são assim designadas por 
partilharem o achado histológico de perfuração epidérmi-
ca com eliminação transepidérmica de tecido conjuntivo 
dérmico, e são em geral divididas de acordo com o tipo 
material expelido e o local da perfuração. Na colagenose 
perfurante reativa são eliminadas sobretudo fibras de co-
lagénio, na EPS fibras elásticas, enquanto nas foliculites 
perfurantes o processo de eliminação ocorre através do 
epitélio do folículo piloso.1-3 
 A EPS é encontrada predominantemente em adoles-
centes e adultos jovens, sendo até três vezes mais fre-
quente no sexo masculino.1
 Esta entidade tem sido tradicionalmente classificada, 
por ordem decrescente de frequência, como idiopática – a 
maioria dos casos, reativa – cerca de 25 - 40%, ou excecio-
nalmente fármaco-induzida.3-5 
 Entre os casos idiopáticos tem sido descrita associação 
familiar, com formas hereditárias autossómicas dominan-
tes ou recessivas.5 A forma reativa pode ocorrer associada 
a síndrome de Down, síndrome de Marfan, síndrome de 
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